Potential Ban on Menthol Cigarettes in the US

Jul.05.2022
Potential Ban on Menthol Cigarettes in the US
A proposed ban on menthol-flavored tobacco products in the US could result in 16,250 fewer tobacco-related deaths by 2060.

In April of last year, the US Food and Drug Administration (FDA) announced a proposed ban on menthol-flavored cigarettes and cigars. This was seen as a measure that could significantly reduce smoking rates.


A recent study published in the BMJ Tobacco Control has concluded that a ban on menthol cigarettes could prevent 16,250 tobacco-related deaths annually by 2060. Epidemiology professor Rafael Meza from the University of Michigan School of Public Health stated that "This work is part of a series of projects aimed at evaluating the impact of a menthol ban on smoking and health. Our findings demonstrate significant health benefits from a menthol ban and emphasize the urgency of its eventual approval and implementation.


The investigation results were based on an analysis of compiled data and computational modeling infrastructure from a portion of the Tobacco Regulatory Science Center. The research team utilized traditional cigarette and electronic cigarette models, which were previously developed simulation models, to study the impact of menthol and non-menthol cigarettes on the behavior of traditional cigarettes and e-cigarettes.


A new study has found that with a ban on menthol cigarettes, the combined smoking of both menthol and non-menthol cigarettes will decrease by 15% by 2026. The study also predicts a decrease in smoking and e-cigarette related deaths by approximately 5%. This reduction in deaths would result in a decrease of 16,250 deaths per year over the course of 40 years.


As such, the FDA has recently announced a ban on menthol, which has been a topic of long-standing debate. The negotiation process has been opened, and comments will be accepted until July 5th.


Canada's Ban on Menthol Cigarettes


Data from Canada shows that a local ban on menthol cigarettes has had a positive impact on smoking cessation rates. Research suggests that, given the popularity of menthol cigarettes in the United States, implementing a similar ban in that country would provide even greater benefits. According to Geoffrey Fong, Chief Investigator of the International Tobacco Control Policy Evaluation Project, "Based on our survey results, we estimate that a ban on menthol cigarettes in the US would lead to an additional 923,000 smokers quitting, including 230,000 African American smokers.


Further data confirms the effectiveness of the ban on menthol cigarettes.


Meanwhile, a recent study published in JAMA Internal Medicine found that the ban on menthol-flavored cigarettes in Massachusetts resulted in a statewide decrease in cigarette sales. The study, titled "Massachusetts' Cigarette Sales and Comprehensive Menthol Ban," reported that after the menthol flavor ban went into effect, cigarette sales in Massachusetts dropped by as much as 33%.


According to researchers, during the same period, cigarette sales decreased by 8% in 33 states that did not implement a ban on menthol flavoring, while sales of menthol-flavored cigarettes decreased by 3%. UPI quoted Samuel Asare, co-author of the Sid study, as saying, "We have learned from Massachusetts that the ban on menthol flavoring effectively reduced sales of menthol and overall cigarettes.


This article has been compiled from third-party information for the purpose of educational exchange. The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
According to CBS Los Angeles on August 27, 2026, California lawmakers have passed Assembly Bill 762, which would phase out disposable, battery-embedded nicotine vapes in the state. If signed by Governor Gavin Newsom, manufacturing and importation of the covered products would be prohibited beginning January 1, 2027, followed by a sales ban on January 1, 2028. Driven primarily by concerns over electronic waste, lithium-battery fires and environmental pollution, the legislation would further shift California’s legal vape market toward rechargeable, refillable or replaceable-pod devices.
Aug.28
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
RELX and UK e-liquid brand T-Juice have launched the Prime Pro × Red Astaire bundle in France, combining the RELX Prime Pro open-system pod device with T-Juice’s signature Red Astaire nicotine salt e-liquid. The collaboration retains the existing Prime Pro hardware platform while using an established flavor brand to create a complete open-system offering. The product appeared in French retail and distribution channels in August 2026 and represents a co-branded retail bundle rather than a new device launch.
Aug.27
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's liquid-vape market is showing changes across raw-material imports, product types and sales channels after synthetic nicotine came under the Tobacco Business Act on April 24. Customs data show nicotine-analogue imports totaled 12,126 kilograms from April through August, while synthetic-nicotine imports over the same five months totaled 231,663 kilograms, just 39.3% of the amount imported in March alone. Physical liquid-vape stores tracked in Seoul and Gyeonggi Province fell 9.9%, unmanned outlets edged higher and online sales listings increased from 27,774 to 42,437. Government testing of 105 liquid inhalation products promoted as nicotine-free separately found nicotine in 13 and 6-methylnicotine in 12.
Sep.22